MariMed (MRMD) Q2 EPS Jumps to Positive
MariMed (OTC:MRMD), a multi-state cannabis operator focusing on branded consumer packaged goods, reported its Q2 2025 earnings on August 6, 2025. The company's most important news was a solid beat on non-GAAP earnings per share, reporting $0.40 non-GAAP EPS versus a $(0.01) loss expected by analysts. However, revenue (GAAP) came in at $39.6 million, missing the $40.93 million GAAP revenue consensus and Revenue decreased compared to Q2 2024. Adjusted EBITDA (non-GAAP) improved sequentially but declined year over year, led by ongoing wholesale growth from Q1 2025 but partially offset by continuing margin pressure. The quarter underscored positive progress in expansion and innovation but also revealed persistent headwinds in retail sales and pricing.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
MariMed is a vertically integrated cannabis operator with branded products sold across wholesale and retail channels in multiple states. Its business centers on developing proprietary brands for flower, edibles, and wellness products, then distributing these through company-owned dispensaries and third-party retail shops.
Source Fool.com
